source
- FDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal🟢 FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitation: Axsome said up to 76% of patients with Alzheimer’s disease have agitation, which is characterized by pacing, restlessness an…Endpoints · 3mo ago↗ source
- STAT+: Axsome wins FDA nod for Alzheimer’s agitationVinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and moreThe FDA proposed excluding the active ingredients in popular obesity and diabetes drugs from a list of substances that can be used for compounded versions